Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Giuliani, Jacopo, Bonetti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094077/
https://www.ncbi.nlm.nih.gov/pubmed/35582308
http://dx.doi.org/10.20517/cdr.2021.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094077/
https://www.ncbi.nlm.nih.gov/pubmed/35582308
http://dx.doi.org/10.20517/cdr.2021.14

Ejemplares similares